SCHEMBL22817639

SCHEMBL22817639

CCC(C)(C)c1c(C)[nH]c(C)cc1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.34
▸ CYP1A2 P05177 2/20 0.34
▸ GAA P10253 2/20 0.34
▸ ALDH1A1 P00352 5/20 0.34
▸ HSD17B10 Q99714 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ ADORA1 P30542 2/20 0.33
▸ MAPT P10636 1/20 0.33
▸ CA1 P00915 1/20 0.32
▸ HPGD P15428 4/20 0.32
▸ MAPK1 P28482 3/20 0.32
▸ POLB P06746 1/20 0.32
▸ LMNA P02545 3/20 0.32
▸ KEAP1 Q14145 1/20 0.32
▸ NFE2L2 Q16236 1/20 0.32
▸ SMN1; SMN2 Q16637 3/20 0.31
▸ PKM P14618 1/20 0.31
▸ NPC1 O15118 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22817640 0.80 KDM4E (0.38) KDM4ECYP1A2GAAALDH1A1HSD17B10
SCHEMBL22817645 0.80 KDM4E (0.31) KDM4ECYP1A2GAAALDH1A1HSD17B10
SCHEMBL15459460 0.68 HSD17B10 (0.43) KDM4ECYP1A2GAAALDH1A1HSD17B10
SCHEMBL9881406 0.67 KDM4E (0.37) KDM4ECYP1A2GAAALDH1A1HSD17B10
SCHEMBL21341793 0.66 KDM4E (0.43) KDM4ECYP1A2GAAALDH1A1HSD17B10
SCHEMBL9136107 0.65 KDM4E (0.42) KDM4ECYP1A2GAAALDH1A1HSD17B10
SCHEMBL4478455 0.63 HPGD (0.46) KDM4ECYP1A2GAAALDH1A1ADORA1
SCHEMBL15818859 0.63 KDM4E (0.37) KDM4ECYP1A2GAAALDH1A1HSD17B10
SCHEMBL24367843 0.62 AHR (0.50) KDM4ECYP1A2GAAALDH1A1MEN1
SCHEMBL12989131 0.62 KDM4E (0.47) KDM4EPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661421-B2 Indolizine compounds, preparation method and use thereof HAIHE BIOPHARMA CO., LTD. (CN) 2023-05-30 — — US disclosed
US-20200399270-A1 INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF HAIHE BIOPHARMA CO., LTD. (CN) 2020-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11661421-B2 Indolizine compounds, preparation method and use thereof EZH1, EZH2, IKZF3 KDM4E 61/4885CYP1A2 2785/4885GAA 4298/4885
US-20200399270-A1 INDOLIZINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF EZH1, EZH2, IKZF3 KDM4E 61/4885CYP1A2 2785/4885GAA 4298/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback